Akums Drugs and Pharmaceuticals block deals, bulk deals, insider trading and stake changes
NSE: AKUMSBSE: 544222Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹680.20.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹10,530 Cr630th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 8 Aug 2026
- 36.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 3.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.45%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 8 Aug 2026
- 9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 8 Aug 2026
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,89,38152.3% delivered
Promoter and insider buying and selling
Trades made since 23 Oct 2025.Akums Drugs and Pharmaceuticals promoter holding
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade
Akums Drugs and Pharmaceuticals insider trading
All 5 disclosures on record.Insider trading, all companies
Aug 2026
- Sajan Shashidharan₹0.15 Cr2,000 sharesSold or invoked · Designated Person · 13 Aug 2026 · disclosed 30 Sep
- Sajan Shashidharan₹0.15 Cr2,000 sharesBought · Designated Person · 13 Aug 2026 · disclosed 30 Sep
Feb 2025
- Suman₹0.04 Cr880 sharesPledge · Designated Person · 17 Feb 2025 · disclosed 10 Mar
- Suman₹0.02 Cr380 sharesBought · Designated Person · 17 Feb 2025 · disclosed 10 Mar
- Suman₹0.06 Cr1,328 sharesSold or invoked · Designated Person · 17 Feb 2025 · disclosed 10 Mar
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Akums Drugs and Pharmaceuticals stake sales and purchases
1 disclosure on record.
Dec 2025
- SoldRuby Qc Investment Holdings Pte Limited4.62% of the company72,78,535 sharesholds none after22 Dec 2025 · filed under the 2% rule
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Akums Drugs and Pharmaceuticals block deals and bulk deals
Last 12 months, since 23 Oct 2025: 1 block deal and 1 bulk deal, ₹623 Cr bought and ₹623 Cr sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Monday 22 Dec 20254 firms · ₹623 Cr bought · ₹623 Cr soldNet nil
- BoughtICICI PRUDENTIAL MUTUAL FUNDBlock dealBought 72,78,535 at ₹428.004.62% of the company₹312 Cr
- BoughtICICI PRUDENTIAL MUTUAL FUNDBought 72,78,535 at ₹428.004.62% of the company₹312 Cr
- SoldRUBY QC INVESTMENT HOLDINGS PTE.LTD.Block dealSold 72,78,535 at ₹428.004.62% of the company₹312 Cr
- SoldRUBY QC INVESTMENT HOLDINGS PTE.LTD.Sold 72,78,535 at ₹428.004.62% of the company₹312 Cr
Tuesday 6 Aug 20241 firm · ₹195 Cr bought · ₹0 soldNet bought ₹195 Cr
- BoughtSMALLCAP WORLD FUND INCBought 25,86,541 at ₹753.841.64% of the company₹195 Cr
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 3 deals on record since listing on 6 Aug 2024.